By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Mating injuries may lead scientists to identify dinosaurs’ sex - 2What you need to know about Trump accounts as Michael and Susan Dell donate $6 billion to the new early childhood investment program
- 3Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
- 4Midlife weight gain can start long before menopause – but you can take steps early on to help your body weather the hormonal shift
- 5Blood pressure drug recalled for possible cross-contamination
- The Fate of Gaming: 5 Energizing Advancements Not too far off
- Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how
- The 15 Best Business visionaries Under 40
- 6 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- Which Espresso Do You Like Best? Vote
- Windows to the Previous: An Excursion Through the World's Notable Engineering
- Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- Tech Patterns: Contraptions That Will Shape What's in store
